Peer-influenced content. Sources you trust. No registration required. This is HCN.
Hospitalized patients who had advanced COVID-19 with lung involvement and who received the antiviral agent remdesivir (Gilead Sciences) recovered faster than similar patients who received placebo, according to a preliminary data analysis from a US-led randomized, controlled trial.
Family Medicine/General Practice May 4th 2020
This feature article from the BMJ discusses how and why American oncologists are rushing to prioritize the patients at greatest risk, institute new protections, and learn from their collective experiences during the COVID-19 pandemic.
Although the findings reported in Blood should be considered as hypothesis-generating and preliminary in nature, a small clinical trial suggested ibrutinib may protect against lung injury and improve pulmonary function in hypoxic patients with COVID-19.
Allergy & Immunology April 27th 2020
JAMA Network
A JAMA “Original Investigation” seeks to discover the characteristics, clinical presentation, and outcomes of 5,700 patients hospitalized with COVID-19 in the United States, specifically in the New York City area.
Beyond converting to telehealth platforms and limiting in-office visits, the Best Practices Committee of the NCCN shares essential approaches to help mitigate the transmission of COVID-19 among patients with cancer and the health care workers who treat them.
Allergy & Immunology April 20th 2020
This study in Cancer suggests the possibility, pointing to qualitative results of clinical trial principal investigators, research staff, referring clinicians, and cancer center leaders regarding their attitudes and experiences with enrolling minority patients in cancer clinical trials.
Family Medicine/General Practice April 20th 2020